Skip to main content

Table 2 Anti-amyloid antibodies in early AD trials: clinical efficacy, safety, and PET imaging effects

From: Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval

Antibody Antibody type Target amyloid species Clinical efficacy PET imaging Safety profile
Aducanumab
Biogen
IgG1 human
N-terminal
Plaque, fibrils > > oligomers ADAS-cog 27%
CDR-SB 22%
Amyloid PET ~ 80%
Tau PET: significant reduction
ARIA-E 35%
ARIA-H 18%
Headache 20%
Gantenerumab
Roche
IgG1 human
N-terminal and central
Plaque, fibrils, and oligomers ADAS-cog: no effect to date, phase 3 ongoing
CDR-SB: no effect to date, phase 3 ongoing
Amyloid PET ~ 75%
Tau PET: not evaluated
ARIA-E 28–42%
ARIA-H 15–25%
Injection site erythema 13%
BAN2401
Eisai
IgG1
humanized
N-terminal
Large oligomers (protofibrils)
> plaque
ADAS-cog 47%
CDR-SB 26%
Amyloid PET ~ 90%
Tau PET: not evaluated
ARIA-E 10%
ARIA-H: not reported
Infusion reactions leading to discontinuations 2.5%
  1. Abbreviations: IgG immunoglobulin G, PET positron emission tomography, ARIA-E amyloid-related imaging abnormalities with effusion or edema, ARIA-H amyloid-related imaging abnormalities with hemosiderin deposits
  2. Data sources for target amyloid species: aducanumab [10, 11]; gantenerumab [12, 13, 20]; BAN2401 [10, 14]. Data sources for clinical and imaging data: aducanumab [11, 19]; gantenerumab [13, 20,21,22]; BAN2401 [23, 25]